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Autophagy is induced during differentiation of human monocytes into macrophages that is mediated by CSF1/CSF-
1/M-CSF (colony stimulating factor 1 [macrophage]). However, little is known about the molecular mechanisms that link
CSF1 receptor engagement to the induction of autophagy. Here we show that the CAMKK2-PRKAA1-ULK1 pathway is
required for CSF1-induced autophagy and human monocyte differentiation. We reveal that this pathway links P2RY6 to
the induction of autophagy, and we decipher the signaling network that links the CSF1 receptor to P2RY6-mediated
autophagy and monocyte differentiation. In addition, we show that the physiological P2RY6 ligand UDP and the
speciﬁc P2RY6 agonist MRS2693 can restore normal monocyte differentiation through reinduction of autophagy in
primary myeloid cells from some but not all chronic myelomonocytic leukemia (CMML) patients. Collectively, our
ﬁndings highlight an essential role for PRKAA1-mediated autophagy during differentiation of human monocytes and
pave the way for future therapeutic interventions for CMML.
Introduction
Monocytes have the unique property among peripheral blood
cells of migrating into tissues and further differentiating into
morphologically and functionally heterogeneous cells that
include macrophages, myeloid dendritic cells, and osteoclasts.1,2
In the absence of differentiation, circulating monocytes are
believed to undergo apoptotic cell death. Once stimulated by an
inflammatory response, monocytes activate prosurvival pathways,
migrate to tissues, and differentiate into macrophages.3 The
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differentiation of human peripheral blood monocytes into mac-
rophages can be recapitulated ex vivo by CSF1.4 Previous studies
have established that physiological monocyte differentiation trig-
gered by CSF1R (colony stimulating factor 1 receptor) engage-
ment is critically dependent on the formation of a
multimolecular complex consisting of FADD (Fas [TNFRSF6]-
associated via death domain), CFLAR/FLIP (CASP8 and
FADD-apoptosis regulator), CASP8/caspase-8, RIPK1 (receptor
[TNFRSF]-interacting serine-threonine kinase 1) and other pro-
tein partners; CASP8 acts as the initiatory caspase in this pro-
cess.5,6 More recently, we have established that autophagy also
plays a crucial role during CSF1-induced differentiation of
monocytes.7,8
Autophagy (macroautophagy) is an evolutionarily conserved
catabolic pathway that delivers cytoplasmic substrates, such as
damaged organelles and cytoplasmic proteins, to lysosomes for
degradation.9,10 There is growing evidence that supports a role of
autophagy in the rapid cellular changes that are necessary for
proper differentiation of different cell types.11–13 However, the
molecular mechanisms that regulate autophagy in the context of
cell differentiation have remained largely unexplored. The induc-
tion of autophagy critically requires ULK1 (unc-51 like autoph-
agy activating kinase 1), which acts in a multimolecular complex
to initiate autophagy.14 ULK1 phosphorylation on Ser555 by
PRKAA/AMPK (protein kinase, AMP-activated) is one of the
main mechanisms leading to the induction of autophagy via the
phosphorylation and activation of PIK3C3/VPS34.15
Results from studies presented herein establish the complete
signaling pathway that links CSF1R engagement to the induction
of autophagy and differentiation of monocytes into macrophages.
We found that CSF1 increases the expression of the purinergic
receptor P2RY6 and activates the CAMKK2-PRKAA1-ULK1
pathway that is responsible for autophagy induction. Notably,
inhibition of this pathway using pharmacological inhibitors,
siRNA approaches, and prkag1/ampkg1 knockout mice, abro-
gated CSF1-mediated induction of autophagy and
differentiation.
A pathological situation in which the differentiation of
monocytes is clearly altered is chronic myelomonocytic leuke-
mia (CMML).16 CMML is associated with monocytosis and
characterized by defects in monocyte to macrophage differen-
tiation.17 This defect in differentiation can be attributed to
the presence of immature dysplastic granulocytes that secrete
high levels of a-defensins DEFA1/HNP1/2 and DEFA3/
HNP3 that antagonize P2RY6, in CMML patients. We show
that a contingent of immature granulocyte cells that is pres-
ent in variable proportion in CMML patients may affect
PRKAA activation in leukemic monocytes. In light of this
observation, we showed that triggering P2RY6 with its physi-
ological ligand (UDP) or the P2RY6 agonist could restore
autophagy and normal differentiation of monocytes in some
but not all CMML patients. Collectively our findings high-
light an essential role for P2RY6-mediated autophagy through
PRKAA activation during the differentiation of human
monocytes and pave the way for future therapeutic interven-
tions for CMML.
Results
CSF1-induced differentiation of monocytes is associated
with the induction and activation of PRKAA1/AMPKa1
When stimulated with CSF1, human monocytes differentiate
into macrophages as shown by an increase in cell adherence and
the acquisition of specific markers such as TFRC/CD71 and
CD163. After 4 d, more than 80% of myeloid cells were found
to be positive for TFRC and CD163 expression (Fig. 1A), and
increased cell surface expression correlated with a rise in TFRC
and CD163 mRNA expression (Figs. S1A and S3A). During dif-
ferentiation, monocytes accumulated the protein kinase AMP-
activated (PRKAA) (Fig. 1B). Increased expression of PRKAA
was detected one d after CSF1 stimulation and was maximal 2 d
later. The CSF1-induced augmentation in PRKAA expression
tightly correlated with increased phosphorylation of PRKAA on
Thr172 (Fig. 1B and C). Indeed, there was a strict correlation
between CSF1-induced expression of PRKAA and its phosphory-
lation on Thr172 during human monocyte differentiation
(Fig. 1C). We next sought to identify the PRKA a catalytic sub-
units (PRKAA1/a1 and/or PRKAA2/a2) expressed during
human monocyte differentiation. Of note, unstimulated mono-
cytes exhibited undetectable levels of the PRKAA2/AMPKa2
mRNA and the corresponding protein and no induction of
PRKAA2 mRNA was detected during CSF1-mediated monocyte
differentiation, indicating that only PRKAA1/AMPKa1 was
expressed in differentiating human monocytes (Fig. 1D, S1B
and C). Importantly, the increased expression of PRKAA1 was
not accompanied by a concomitant rise in the PRKAA1 mRNA
level, as shown by real-time qPCR analysis (Fig. 1D). These find-
ings suggest that increased expression of PRKAA1 is regulated at
the post-transcriptional level during CSF1-mediated differentia-
tion of human monocytes and accordingly, cycloheximide treat-
ment of monocytes inhibited CSF1-mediated accumulation of
PRKAA1 expression (Fig. 1E).
The CAMKK2-PRKAA1 axis is required for monocyte
differentiation
The increased expression of PRKAA1 during monocyte differ-
entiation prompted us to investigate whether it could play a role
in this process. Pharmacological inhibition of PRKAA1 by dorso-
morphin (DRS, 2 mM) dampened CSF1-induced PRKAA1
phosphorylation on Thr172 (Fig. 2A) and inhibited CSF1-medi-
ated monocyte differentiation, as illustrated by the drastic
decrease in the double-positive TFRCC and CD163C cell popu-
lation at d 2 (Fig. 2B). Accordingly, inhibition of PRKAA1
expression by a specific siRNA resulted in a concomitant decrease
of PRKAA1 phosphorylation on Thr172 and a reduction of the
phosphorylation of PRKAA1 substrates (Fig. 2C). In light of the
effect of DRS on monocyte differentiation, PRKAA1 knockdown
also led to a robust decrease in the double-positive TFRCC and
CD163C cell population (Fig. 2D). It has been previously
reported that STK11/LKB1 and CAMKK2/CaMKKb can phos-
phorylate PRKAA1 on Thr172 resulting in its activation.18,19 Of
note, we found that human monocytes failed to express the
STK11 mRNA (Fig. S2A). To investigate if low or technically
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Figure 1. CSF1-induced differentiation of human monocytes is associated with the induction of PRKAA expression and activation. Human peripheral
blood monocytes from healthy donors were exposed to 100 ng/mL CSF1 for the indicated times. (A) Macrophage differentiation was examined morpho-
logically (ﬁbroblastic shape) and by 2-color ﬂow cytometric analysis. The percentage indicates cells that express both TFRC/CD71 and CD163. (B) Immu-
noblot analysis of PRKAA and phospho-PRKAA (Thr172) in monocytes following CSF1 stimulation. The ratio between phospho-PRKAA protein and ACTB
was determined from 3 independent experiments using the ImageJ software. (C) The ratio of the PRKAA to phospho-PRKAA protein level was deter-
mined from the results of Figure 1B using the ImageJ software. (D) Real-time qPCR analysis of PRKAA1 gene expression in monocytes exposed to
100 ng/mL CSF1 for the indicated times (mean § SD of 3 independent experiments). (E) Immunoblot analysis of PRKAA1 and phospho-PRKAA1 (Thr172)
in monocytes exposed to 100 ng/mL CSF1 alone or in association with 10 mg/mL cycloheximide (CHX), which was added 45 min before CSF1 treatment.
ACTB was detected as the loading control. Each panel is representative of at least 3 independent experiments.
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undetectable levels of STK11 were nevertheless expressed by
human monocytes, we analyzed whether STK11 silencing could
affect CSF1-induced monocyte differentiation. Figure S2B shows
that STK11 silencing failed to strongly affect CSF1-induced
monocyte differentiation, suggesting that STK11 is neither
involved in PRKAA1 phosphorylation nor in the differentiation
of human monocytes induced by CSF1. The efficiency of the
siRNA targeting STK11 was verified in the K562 cell line (Fig.
S2C). To investigate monocyte differentiation in another context,
we treated murine bone marrow monocytes with CSF1. After 4
and 7 d, differentiation of monocytes into macrophages was
assessed by flow cytometry. The ITGAMC/CD11bC and EMR1C
/F4/80C cell population corresponding to macrophages increased
tremendously at d 4 and d 7 (Fig. 2E). As it is the case with puri-
fied human monocytes, PRKAA1 expression and phosphorylation
on Thr172 also increased in murine macrophages (Fig. 2F).
Figure 2. PRKAA1 is required
for macrophagic differentiation of
monocytes. (A) Human monocytes
were exposed for 2 d to 100 ng/mL
CSF1 alone or in combination with
2 mM DRS, which was added
45 min before CSF1 treatment. The
expression of PRKAA1, Phospho-
PRKAA1 and Phospho-PRKAA sub-
strates was analyzed by immuno-
blotting. (B) Human monocytes
were exposed for 2 d to 100 ng/mL
CSF1 alone or in combination with
2 mM DRS, which was added
45 min before CSF1 treatment. Dif-
ferentiation was measured as
described in Figure 1A. (C) Mono-
cytes were transfected with siRNAs
targeting LUCIFERASE (LUC) or
PRKAA1 and exposed 2 d to 100 ng/
mL CSF1. The expression of PRKAA1,
Phospho-PRKAA1 and Phospho-
PRKAA substrates was analyzed by
immunoblotting. (D) Monocytes
were transfected with siRNA target-
ing LUCIFERASE (LUC) or PRKAA1 and
exposed for 2 d to CSF1. Differentia-
tion was assessed as described in
Figure 1A. (E) Enriched bone mar-
row murine monocytes were
exposed for the indicated time to
100 ng/mL CSF1. Differentiation was
studied by morphological examina-
tion (ﬁbroblastic shape) and by 2-
color ﬂow cytometry analysis at indi-
cated day. Percentages indicate cells
that express both high ITGAM/
CD11b and EMR1/F4/80 staining. (F)
Immunoblot analysis of PRKAA1 and
phospho-PRKAA1 (Thr172) in mono-
cytes following CSF1 stimulation. (G)
Immunoblot analysis of PRKAG1/
AMPKg1 and PRKAA1 in monocytes
obtained from WT or prkag1¡/- mice
(n D 2). ACTB was detected as a
loading control. (H) Monocytes
obtained from WT or prkag1¡/- mice
were exposed for the indicated
times to 100 ng/mL CSF1. Differenti-
ation was assessed as described in
Figure 2E. For each experiment,
ACTB was detected as the loading
control. Each panel is representative
of at least 3 independent
experiments.
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Finally, to specifically assess the role of PRKAA1 in the differentia-
tion process, we stimulated bone marrow monocytes from wild-
type and prkag1¡/- mice for 4 d with CSF1. As already reported,
PRKAG1 deficiency led to a drastic reduction of PRKAA1 expres-
sion20 in 2 different transgenic mice (Fig. 2G) and to a concomi-
tant inhibition of monocyte differentiation (Fig. 2H). All
together, these findings highlight the key role of PRKAA1 in
monocyte differentiation in 2 different contexts.
Next, we hypothesized that CAMKK2 might act as the
upstream kinase responsible for PRKAA1 phosphorylation and
activation in human monocytes. Accordingly, the specific
CAMKK2 inhibitor ST0–609 was as efficient as DRS in inhibit-
ing the phosphorylation of PRKAA1 on Thr172 and PRKAA
substrates (Fig. 3A) and the CSF1-induced differentiation of
human monocytes (Fig. 3B). The importance of CAMKK2 in
this process was further highlighted using a siRNA that specifi-
cally targeted CAMKK2 (Fig. 3C). CAMKK2 silencing resulted
in decreased phosphorylation of PRKAA1 on Thr172 and the
inhibition of monocyte differentiation, similar to knockdown of
PRKAA1 (Fig. 3D). Furthermore, pharmacological inhibition of
CAMKK2 by STO-609 or PRKAA by DRS or knockdown of
CAMKK2 or PRKAA1 furthermore induced a significant decrease
in the phagocytic function of macrophages (Fig. 3E and F).
Taken together our data clearly illustrate a key role of the
CAMKK2-PRKAA1 axis in the differentiation of monocytes
into macrophages and the acquisition of phagocytic function.
PLCG2 downstream of the CSF1 receptor is required for
monocyte differentiation but not PRKAA1 activation
To further decipher the signaling events that link the CSF1
receptor to the induction of monocyte differentiation, we next
studied the implication of calcium release that is a prerequisite
for CAMKK2 activation.21 It is well established that PLCG2
interacts with the CSF1 receptor to induce Ca2C release.22
Accordingly, CSF1 triggered a rapid release of Ca2C in human
monocytes that was abrogated by the pan-phospholipase C
(PLC) inhibitor U73122 (Fig. 4A). U73122 also inhibited
CSF1-mediated PLCG2 and PRKAA1 phosphorylation on
Thr172, suggesting that the effect of CSF1 on PRKAA1 phos-
phorylation is dependent on PLC (Fig. 4B). Of note, knock-
down of the CSF1R decreased PRKAA1 expression and
phosphorylation in identical conditions (Fig. 4C). Finally,
knockdown of PLCG2 failed to affect CSF1-induced PRKAA1
phosphorylation at d one (Fig. 4C) but efficiently inhibited
CSF1-induced monocyte differentiation at d 2 (Fig. 4D and E).
Collectively, these findings show that PLCG2 which acts down-
stream of CSF1 receptor activation is required for CSF1-induced
differentiation of human monocytes but is dispensable for
PRKAA1 phosphorylation and activation.
P2RY6 engagement activates the PLCB3-CAMKK2-
PRKAA1 pathway that promotes human monocyte
differentiation
We previously reported that P2RY6 is required for CSF1-
induced human monocyte differentiation.17 In line with this
observation, we postulated that the CAMKK2-PRKAA1 pathway
was triggered following an engagement of P2RY6. CSF1 was
observed to significantly increase P2RY6 mRNA levels, while
mRNA expression of other P2Y receptors was reduced in identi-
cal conditions (Fig. S3A). Increased expression of P2RY6 mRNA
by CSF1 was associated with an increased cell surface expression
of P2RY6 (Fig. S3B). In addition, confocal microscopy images,
showed numerous puncta of CSF1 and P2Y6 receptor colocaliza-
tion at the cell surface of differentiated monocytes (Fig. S4A).
Moreover, specific silencing of the CSF1R decreased P2RY6
expression at the cell surface (Fig. S4B). Together, these results
strongly suggest an interrelation of both receptors during mono-
cyte differentiation.
Importantly, stimulation of monocytes with UDP, a physio-
logical ligand of P2RY6, induced an increase of PRKAA1 expres-
sion and phosphorylation similar to that observed with CSF1. In
both situations, the signal was abrogated by the P2RY6
antagonist MRS2578 (5 mM) (Fig. 5A). As expected,
CAMKK2 inhibition by STO-609 also abrogated CSF1 or
UDP-induced PRKAA1 phosphorylation. In addition, inhibition
of P2RY6 by MRS2578 resulted in a significant inhibition of
CSF1-mediated monocyte differentiation (Fig. 5B) and phago-
cytic function (Fig. 5C). Of note, the specific P2RY1 antagonist,
MRS2179 failed to affect CSF1-induced monocyte differentia-
tion in identical conditions (Fig. S5A). In addition and contrary
to MRS2578, MRS2179 did not affect PRKAA1 phosphoryla-
tion on Thr172 (Fig. S5B). All together these data highlight the
specific role of P2RY6 in the regulation of PRKAA1 activation
and monocyte differentiation. To gain insights into PRKAA1
regulation during monocyte differentiation, we took advantage
of a siRNA approach aimed at individually inhibiting the expres-
sion of P2RY6 or PLCB3. PLCB3 has been reported as the spe-
cific PLC isoform that is activated downstream of P2RY6.23
Individual silencing of both proteins induced a significant inhibi-
tion of PRKAA1 expression and phosphorylation on Thr172 in
monocytes stimulated for one d with CSF1 (Fig. 5D). Because it
has been recently demonstrated that the P2RY6 antibody com-
monly used for western blot detection of P2RY6 was poorly spe-
cific,24 we verified P2RY6 expression using a specific monoclonal
antibody that recognizes the native form of P2RY6 using flow
cytometry and immunofluorescence. As shown in Figure 5E,
P2RY6 silencing could be efficiently validated with this antibody
by flow cytometry analysis and immunofluorescence. Of note,
P2RY6 and PLCB3 knockdown potently inhibited CSF1-medi-
ated monocyte differentiation at d 2 (Fig. 5F). Taken together,
these findings show that P2RY6 signaling activates the PLCB3-
CAMKK2-PRKAA1 pathway in CSF1-treated monocytes.
The P2RY6-PRKAA1 pathway mediates autophagy
induction and monocyte differentiation
Autophagy induction by PRKAA requires ULK1-dependent
phosphorylation and activation of PIK3C3/VPS34.14,25 There-
fore, we investigated whether ULK1 was involved in autophagy
induction and monocyte differentiation mediated by CSF1. To
this aim, we used pharmacological and siRNA approaches. As
expected from the results presented in Figure 2B, DRS (2 mM)
prevented an accumulation of the double-positive TFRCC and
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Figure 3. The CAMKK2-PRKAA1 axis is required for human monocyte differentiation. (A) Human monocytes were exposed for 2 d to 100 ng/mL CSF1
alone or in combination with 2 mM DRS or 10 mM STO-609, which were added 45 min before CSF1 treatment. The expression of PRKAA1, Phospho-
PRKAA1 and Phospho-PRKAA substrates was analyzed by immunoblotting. (B) Human monocytes were exposed for 2 d to 100 ng/mL CSF1 alone or in
combination with either 2 mM DRS or 10 mM STO-609, which were added 45 min before CSF1 treatment. Differentiation was examined as described in
Figure 1A. (C) Monocytes were transfected with siRNA targeting LUCIFERASE (LUC), CAMKK2 or PRKAA1 and exposed for 2 d to 100 ng/mL CSF1. Expres-
sion of CAMKK2, PRKAA1, and Phospho-PRKAA1 was analyzed by immunoblotting. (D) Monocytes were transfected with siRNA and treated as in Fig-
ure 3C. Differentiation was examined as previously described. (E) Functional assay of monocytes exposed for 2 d to 100 ng/mL CSF1 alone or in
combination with 2 mM DRS or 10 mM STO-609. The results are expressed as the number of phagocytosed bacteria per cell and represent the mean §
SD of 4 independent experiments performed in triplicate. *P< 0.05 and **P< 0.01 (vs. untreated cells) according to a Student paired t test. (F) Functional
assay of monocytes transfected with LUCIFERASE (LUC), CAMKK2, or PRKAA1 siRNA and treated for 2 d with CSF1. The results are expressed as in
Figure 3E **P < 0.01 and **P < 0.001 (vs d2 siLUC) according to a paired Student t test. Each panel is representative of at least 3 independent experiments.
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CD163C cell population that
corresponds to macrophages
(Fig. 6A). Inhibition of differ-
entiation by DRS also corre-
lated with a reduction in the
number of autolysosomes in
cells treated with CSF1 and
DRS, as assessed by the Cyto-
ID assay (Fig. 6B). Of note,
DRS also reduced CSF1-
induced PRKAA1 phosphory-
lation on Thr172 and phos-
phorylation of ULK1 on
Ser555 (Fig. 6C). We also
confirmed that PRKAA1




formation (Fig. 6D). Impor-
tantly, knockdown of PRKAA1
reproduced the effect of DRS,
as shown by the inhibition of
PRKAA1 expression and phos-
phorylation on Thr172, the
reduction of ULK1 phosphor-
ylation on Ser555 and the
decrease in LC3B-I conversion
into LC3B-II (Fig. 6E). More-
over, knockdown of PRKAA1
in mice also dampened the
phagocytic capacity of macro-
phages and the autophagy acti-
vation (Fig. S5C). To further
confirm the linear relation
from CSF1R to PRKAA1-
induced autophagy, we
performed autophagic flux
assays in monocytes treated
with CSF1 with or without
bafilomycin A1 in conditions
in which PRKAA1 is downre-
gulated or inhibited using
siRNA or pharmacological
inhibitors respectively (Fig. 6F
and Fig. S5D). We found that
both approaches reduced the
conversion of LC3B-I to
LC3B-II, indicating an inhibi-
tion of the autophagic flux in
monocytes treated with CSF1.
These findings confirm the key
role of PRKAA1 regulation
during differentiation of
monocytes. Finally, in contrast
to the P2RY1 antagonist
Figure 4. PLCG2 downstream of the CSF1 receptor is involved in monocyte differentiation but not in PRKAA1
activation. (A) Monocytes were loaded using the Fluo-4 Direct Calcium Assay kit and stimulated with 100 ng/mL
CSF1 alone or in combination with one mM U73122. Calcium ﬂuxes are expressed as the median of the ﬂuores-
cence Intensity (MFI, arbitrary unit) and represent the mean § SD of 3 independent experiments performed in
duplicate. (B) Human monocytes were exposed for one d to 100 ng/mL CSF1 alone or in combination with
either 10 mM STO-609 or 1 mM U73122, which were added 45 min before CSF1 treatment. The expression of
Phospho-PLCG2, PRKAA1, Phospho-PRKAA1 and Phospho-PRKAA substrates was analyzed by immunoblotting.
(C) Monocytes were transfected with siRNAs targeting LUCIFERASE (LUC), CSF1R or PLCG2 and exposed for one d
to 100 ng/ml CSF1. The expression of the different proteins was analyzed by immunoblotting. (D and E) Mono-
cytes were transfected with siRNAs targeting LUCIFERASE (LUC), or PLCG2 and exposed for 2 d to 100 ng/ml
CSF1. The expression of PLCG2 was analyzed by immunoblotting (D), and differentiation was evaluated as
described previously (E). Each panel is representative of at least 3 independent experiments.
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MRS2179, the P2RY6 antagonist MRS2578 inhibited both
monocyte differentiation and LC3B-II conversion, highlighting
the specific role of P2RY6 in the regulation of autophagy
(Fig. S5B). All together, our findings established that the P2RY6-
PRKAA1-ULK1 pathway is required for CSF1-mediated induction
of autophagy and differentiation of human monocytes.
Impaired monocyte differentiation in CMML patients can
be overcome by UDP and P2RY6 agonists through PRKAA1
reactivation
We previously established the occurrence of an immature
CD14¡ and CD24C granulocytic subpopulation that represses
the differentiation of the CD14C and CD24¡ patient’s blasts in
Figure 5. For ﬁgure legend, see page 1122.
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CMML patients.17 This CD14¡ and CD24C population, which
arose from the same leukemic clone than as the CD14C and
CD24¡ population produces high levels of a defensins that in
turn block the differentiation of CD14C and CD24¡ monocytes
through inhibition of P2RY6 signaling. As shown in Figure 7A,
incubation of both CD14C and CD24¡, as well as CD14¡ and
CD24C (representing 27.5% of total cells) cells isolated from a
CMML patient with CSF1 resulted in altered monocyte differenti-
ation of CD14C and CD24¡ cells (49.9% TFRCC cells versus
89.9% in cells depleted from the suppressive CD14¡ and CD24C
subpopulation). Normal CSF1-induced monocyte differentiation
was restored by the physiological P2RY6 ligand UDP (100 mM)
(71.6% TFRCC cells) or the P2RY6 agonist MRS2693 (30 mM)
(98.5% TFRCC cells). To investigate the potential role of
PRKAA1 in the effect of P2RY6 agonists, we searched for
PRKAA1 expression and autophagy induction in monocytes from
a CMML patient treated with CSF1. After 4 d of treatment, there
was a significant increase in both PRKAA1 expression and phos-
phorylation on Thr172 in monocytes from CMML patients
treated with the combination of CSF1 and UDP compared with
CMML patients treated with CSF1 alone (Fig. 7B and C). This
increase in PRKAA1 activation correlated both with a higher level
of differentiation (Fig. 7A) and an increase in the conversion of
LC3B-I into LC3B-II (Fig. 7B). A similar situation was observed
when monocytes from CMML patients were incubated with a
combination of CSF1 and MRS2693 (Fig. 7A and B). Increased
PRKAA1 expression was confirmed by quantification of the
PRKAA1/ACTB ratio in cells from CMML patients treated with
a combination of CSF1 plus UDP or MRS2693 (Fig. 7C). Taken
together, our data show that the defect in CSF1-mediated autoph-
agy and monocyte differentiation found in CMML patients can
be overcome by P2Y6 engagement.
The same experiments were reproduced with 2 other CMML
patients. Figure S6 illustrated the result obtained with 2 represen-
tative patients that exhibited a high level of CD14¡ and CD24C
granulocytic subpopulation (44% and 67%). The coculture of
CD14C and CD24¡ monocytes with CD14¡ and CD24C gran-
ulocytic subpopulation was found to abolish PRKAA1 expression
and phosphorylation, as is also the case for the first patient
(Fig. 7). However, UDP or MRS was unable to restore signifi-
cant PRKAA1 expression and phosphorylation in this patient.
Globally, it appears that a contingent, higher than 30%, of the
CD14¡ and CD24C granulocytic subpopulation exerted an inhi-
bition of PRKAA1 activity and differentiation that cannot be
overcome with P2RY6 agonists.
Discussion
Autophagy is an evolutionarily conserved catabolic process for
the degradation of long-lived molecules and organelles that also
plays a crucial role during the differentiation of a wide range of
cell types.26–28 Notably, the differentiation of hematopoietic cells
requires intense energy consumption, membrane remodeling
and/or organelles elimination, as exemplified for myeloid, mega-
karyocytic, or erythroid differentiation.7,11,29,30 Physiological
monocyte differentiation triggered by CSF1R engagement
requires the formation of a multimolecular complex consisting of
FADD, CFLAR/FLIP, CASP8, RIPK1 and other protein part-
ners; and CASP8 acts as the initiatory caspase to induce the cleav-
age of key protein substrates (such as RIPK1 and
NUCLEOPHOSMIN, among others) that orchestrate the differ-
entiation process.6,31 Accordingly, inhibition of caspase activa-
tion with pancaspase inhibitors or by CASP8 silencing is
sufficient to dampen the differentiation of human monocytes
into macrophages. More recently we established that the induc-
tion of autophagy is also a prerequisite for CSF1-induced mono-
cyte differentiation and the acquisition of phagocytic
functions.7,8 In the same line, it has been previously reported
that induction of autophagy is essential for monocyte-macro-
phage differentiation upon CSF2/GM-CSF stimulation. Indeed,
CSF2 induced MAPK8/JNK1 activation to mediate the induc-
tion of autophagy and monocyte survival. The authors also
showed that CSF1 triggered autophagy induction in both human
and murine monocytes and that inhibition of MAPK8 by
SP600125 hampered CSF1-mediated autophagy and SQSTM1/
p62 accumulation.32 Therefore, it would be interesting in further
studies to decipher the interrelation between PRKAA1 and
MAPK8 activation. Nevertheless, the molecular mechanisms that
link the CSF1R to the induction of autophagy remained ill
defined. In the present study we deciphered the complete signal-
ing pathway from CSF1 receptor engagement to the induction of
Figure 5 (See previous page). P2RY6 engagement activates a PLCB3-CAMKK2-PRKAA1 pathway that promotes human monocyte differentiation. (A)
Human monocytes were exposed for one d to 100 ng/mL CSF1 or 100 mM UDP alone or in combination with either 10 mM STO-609 or MRS2578 (3 or 5
mM), which were added 45 min before CSF1 treatment. The expression of PRKAA1 and Phospho-PRKAA1 was analyzed by immunoblotting. (B and C)
Human monocytes were exposed for 2 d to 100 ng/mL CSF1 alone or in combination with 5 mM MRS2578, which was added 45 min before CSF1 treat-
ment. (B) Differentiation was examined as described previously. Percentages indicate cells that express both TFRC/CD11b and CD163. (C) Functional
assay of monocytes exposed for 2 d to 100 ng/mL CSF1 alone or in combination with 5 mMMRS2578. The results are expressed as the number of phago-
cytosed bacteria per cell and represent the mean§ SD of 4 independent experiments performed in triplicate. ***P< 0.001 (vs CSF1 treated cells) accord-
ing to a paired Student t test. (D and E) Monocytes were transfected with siRNA targeting LUCIFERASE (LUC), P2RY6 or PLCB3 and exposed for one d to
100 ng/mL CSF1. (D) The expression of PLCB3, Phospho-PRKAA1 and PRKAA1 was analyzed by immunoblotting. The ratio between phospho-PRKAA1
protein and ACTB was determined from 3 independent experiments using the ImageJ software. *P < 0.05 (vs d1 LUC) according to a paired Student t
test. (E) The expression of P2RY6 in transfected monocytes was analyzed by immunoﬂuorescence and ﬂow cytometry after one d of treatment with
100 ng/mL CSF1. Two representative pictures are shown (nuclear staining in blue and P2RY6 in green, left panel). The results are expressed as the fold
induction compared to LUC siRNA and represent the mean § SD of 3 independent experiments performed in duplicate (Right panel). **P < 0.01 (vs d2
siLUC) according to a paired Student t test. (F) Monocytes were transfected with siRNAs targeting LUCIFERASE (LUC), P2RY6 or PLCB3 and exposed for 2 d
to 100 ng/mL CSF1. Differentiation was examined as previously described. Each panel is representative of at least 3 independent experiments.
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Figure 6. For ﬁgure legend, see page 1124.
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autophagy and monocyte differentiation. Using both pharmaco-
logical and siRNA approaches, we demonstrate that the physio-
logical differentiation of human monocytes into macrophages
upon CSF1R activation requires an induction of autophagy
through the purinergic receptor P2RY6. Accordingly, stimulation
of human monocytes with CSF1 induced P2RY6 mRNA accu-
mulation and increased P2RY6 protein expression at the mono-
cyte cell surface. Among all of the P2Y receptors analyzed in the
present study, the expression of P2RY6 mRNA was solely
induced by CSF1, whereas expression of all other P2Y mRNA
subtypes was reduced, which reinforces the notion of a specific
role of P2RY6 during human monocyte differentiation. There
are few studies in the literature that show that P2Y6 receptor acti-
vation is involved in differentiation processes such as osteogenic,
monocytic, or dopaminergic differentiation.17,33–35 Moreover, it
has been previously reported that P2RY13 activation by ADP
induces autophagy in hepatoma cell lines.36 However to the best
of our knowledge, this is the first description of purinergic recep-
tor-mediated differentiation being dependent on autophagy
induction.
Understanding how physiological monocyte differentiation
occurs at the molecular and cellular levels is obviously a key ques-
tion in cell biology. Here we demonstrate that PLCB3 interacts
with the P2RY6 receptor to induce intracellular Ca2C production
and CAMKK2 activation. CAMKK2 in turn phosphorylated
PRKAA on Thr172, leading to its activation. Once activated,
PRKAA1 is phosphorylated and activates the serine/threonine
kinase ULK1 on Ser555, resulting in the induction of autophagy.
Importantly, inhibition of P2RY6-mediated autophagy induc-
tion using different pharmacological approaches or specific
siRNA directed against PRKAA1 reduced autophagy induction
and inhibited human monocyte differentiation into macrophages
(Fig. 8, left panel). Moreover, inhibition of the P2RY6 pathway
by specific inhibitors (DRS, STO-609, U73122 and MRS2578)
prevented CSF1-induced differentiation of human monocytes
without increasing the rate of cell death, as assessed by ANXA5/
annexin-V staining and PARP1 cleavage (Fig. S7A and S7B).
Furthermore, we also showed that PRKAA1 silencing neither
affected the proliferation status nor the cell cycle of monocytes,
strongly suggesting that the effect of PRKAA1 resides essentially
on its ability to modulate autophagy during monocyte differenti-
ation (Fig. S7C and S7D). The characterization of the molecular
pathways that control monocyte differentiation and more pre-
cisely the discovery of the implication of the P2RY6 signaling
pathway in the regulation of PRKAA1 activation and autophagy
could be of highest interest for the treatment of myeloid malig-
nancies, including CMML. Of note, we have recently identified
a granulocytic subpopulation in the blood of CMML patients
that produces high levels of a-defensins that inhibit the differen-
tiation of monocytes by binding to P2RY6 (Fig. 8, right panel).
Accordingly, depletion of this granulocytic subpopulation
allowed monocytes from CMML patients to fully differentiate
into macrophages. In light of this finding, we show here that
UDP or P2RY6 agonists could restore physiological monocyte
differentiation ex vivo in a blood sample of one CMML patient.
In the other 2 patients tested, that both exhibit a high contingent
of granulocytic subpopulation in the blood (44% and 67%),
PRKAA1 expression, and phosphorylation were drastically
reduced in coculture conversely to isolated CD14C and CD24¡
cells. Importantly in those patients P2RY6 agonists failed to
restore normal monocyte differentiation. Nevertheless, our find-
ings show that in CMML patients, the granulocytic subpopula-
tion exerted a negative constraint on the differentiation of
monocytes that is strikingly correlated to the lack of PRKAA1
expression and activation.
The reinduction of differentiation has been shown to be a valu-
able therapeutic strategy in some hematopoietic malignancies and
has particularly been well exemplified in acute promyelocytic leuke-
mia (APL). APL is caused by an arrest of leukocyte differentiation
at the promyelocyte stage and all-trans retinoic acid (ATRA) treat-
ment, which is able to reinduce differentiation, has transformed
APL from a highly fatal to a highly curable disease.37 Importantly,
the antileukemic and differentiation effect of ATRA in APL has
been recently linked to its ability to induce autophagy-dependent
degradation of the PML-RARA/RARa oncoprotein.38–40
The discovery that P2RY6 ligands such as UDP or P2RY6
agonists are able to restore normal differentiation in some
CMML patients through the PRKAA1 reactivation is exciting.
In agreement with these findings, it has been recently reported
that 5-aminoimidazole-4-carboxamide ribonucleoside, an
PRKAA activator, enhances ATRA-mediated differentiation of
promyelocytic NB4 cells and, as a single agent induces the
expression of cell surface markers associated with mature mono-
cytes and macrophages in the acute myeloid leukemia cell line
Figure 6 (See previous page). The P2RY6-PRKAA1 pathway mediates autophagy induction and monocyte differentiation. (A–C) Human monocytes
were exposed for 2 d to 100 ng/mL CSF1 alone or in combination with 2 mM DRS, which was added 45 min before CSF1 treatment. (A) Differentia-
tion was visualized as described previously. (B) The autolysosome number was quantiﬁed by ﬂow cytometric analysis using a Cyto-ID

Autophagy
Detection Kit. A representative cytometry proﬁle is shown in the upper panel. The results are expressed as the fold induction compared with
untreated cells and represent the mean § SD of 3 independent experiments performed in duplicate (lower panel). ***P < 0.001 (vs untreated
cells) according to a paired Student t test. (C) Immunoblot analysis of the indicated protein is shown. (D and E) Monocytes were transfected with
siRNA targeting LUCIFERASE (LUC) or PRKAA1 and exposed for 2 d to CSF1. (D) Differentiation was examined as described in Figure 1A. Autolyso-
somes were quantiﬁed by ﬂow cytometric analysis using the Cyto-ID

Autophagy Detection Kit. A representative cytometry proﬁle is shown (right
panel). (E) The expression of PRKAA1, Phospho-PRKAA1, Phospho-ULK1, ULK1 and LC3B was analyzed by immunoblotting. (F) Monocytes were
transfected with siRNA targeting LUCIFERASE (LUC) or PRKAA1 and exposed for 2 d to 100 ng/mL CSF1 alone or in association with 15 nM baﬁlo-
mycin A1 (BafA1) added 3 h before the end of CSF1 treatment and protein expression was analyzed by immunoblot. The ratio between LC3B-II
protein and ACTB was determined using the ImageJ software. For all western blot experiments, ACTB was detected as the loading control. Each
panel is representative of at least 3 independent experiments.
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Figure 7. Differentiation defect in CMML patients can be restored by UDP and P2RY6 agonists through PRKAA1 reactivation. (A–C) Following negative
sorting, CD14C and CD24¡ (monocytes), as well as CD14¡ and CD24C (immature granulocytes) populations from one CMML patient were cultured sepa-
rately or together with CSF1 alone or in the presence of 100 mM UDP or 30 mM MRS2693 for the indicated times. (A) Flow cytometric analysis of CD14
and CD24, identifying CD14C and CD24¡, as well as CD14¡ and CD24C cells in the CMML patient. Differentiation was only examined for CD14C cells. (B)
CD14C and CD24¡ (monocytes), as well as CD14¡ and CD24C (immature granulocytes) populations were cultured together with CSF1 alone or in the
presence of 100 mM UDP or MRS2693 (10 or 30 mM) for the indicated times. The expression of PRKAA1, Phospho-PRKAA1, and LC3B was analyzed by
immunoblotting. ACTB was detected as a loading control. (C) The ratio of the phospho-PRKAA1 protein level to that of ACTB protein level was measured
from the protein band signals of Figure 7B, using the ImageJ software.
www.tandfonline.com 1125Autophagy
U937.41 Decitabine and azacitidine are 2 nucleoside analogs that
are currently used as first-line treatments for high-risk MDS and
CMML patients. Indeed, both agents exert potent antileukemic
effects in MDS and CMML.42,43 Therefore, it is tempting to
speculate that part of their antileukemic effect might also involve
an induction of autophagy and myeloid differentiation. Never-
theless, the data presented herein deciphers the signaling path-
ways involved in CSF1-mediated induction of autophagy and
monocyte differentiation, as well as paves a new research avenue
for future therapeutic interventions through PRKAA reactivation
in the context of CMML.
Materials and Methods
Reagents and antibodies
Human CSF1 was purchased from
Miltenyi (130–096–493). Cyclohexi-
mide (C1988) and propidium iodide
(P4170) and RNase A (R6513) were
purchased from Sigma-Aldrich. Dorso-
morphin, STO-609, MRS2578, UDP,
MRS2179, MRS2693 and bafilomycin
A1 were from Tocris (3093, 1551,
2146, 3111, 0900, 2502, and 1334,
respectively) and U73122 (BML-
ST391–0005) was from ENZO Life
Sciences. Antibodies to PRKAA1/2
(detects the a1 and a2 isoforms of the




PLCG2 (Y759), PLCB3, ULK1, phos-
pho-ULK1 (Ser555), and LC3B were
purchased from Cell Signaling Technol-
ogy (2532, 2757, 2535, 5759, 3872,
3874, 2482, 8054, 5869 and 2775,
respectively). ACTB, CSF1R, P2RY6
(SC-20127), STK11/LKB1 and HSP90
antibodies were from Santa Cruz Bio-
technology (sc-1616, sc-692, sc-20127,
sc-32245 and sc-13119, respectively).
PRKAG1/AMPKg1 antibody was from
Abcam (ab32508). HRP-conjugated
rabbit anti-goat or anti-mouse was pur-
chased from Dako (P0449 and P0260)
and HRP-conjugated goat anti-rabbit
was from Cell Signaling Technology
(5127).
Patient samples
Patients and volunteers signed an
informed consent according to the Dec-
laration of Helsinki and recommenda-
tions of an independent scientific
review board. Chronic-phase CMML
diagnosis was based on WHO criteria.
Patients were newly diagnosed or had previously diagnosed
hematopoietic disease and were followed every 3 mo. They were
either untreated or received supportive care or cytotoxic treat-
ment, in most cases hydroxyurea.
Cell culture, cell sorting, and differentiation
Blood samples were collected using ethylene diamine tetraace-
tic acid–containing tubes. Mononucleated cells were first isolated
using Ficoll Hypaque (Eurobio, CMSMSL0101). Then, we used
the autoMACS Pro Separator (Miltenyi, Paris, France) to
perform cell enrichment. An initial negative selection, which
Figure 8. Schematic view of the signaling pathways involved in healthy and CMML monocytes during
CSF1-induced differentiation. Upon CSF1 binding, the CSF1R triggers the activation of the P2RY6-
PLCB3-CAMKK2-PRKAA1-ULK1 pathway leading to induction of autophagy and human monocyte dif-
ferentiation. In a CMML-dependent context, immature dysplastic granulocytes synthesize and secrete
large amounts of a-defensins DEFA1 and DEFA3, which antagonize P2RY6 and inhibit CSF1-induced
differentiation of monocytes.
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included antibodies targeting CD3, CD7, CD16, CD19, CD56,
CD123, and GYPA/glycophorin A, was used for monocyte
enrichment (Miltenyi, 130–091–153). In CMML samples,
CD14C and CD14¡ populations were further enriched using an
anti-CD14 antibody (Miltenyi, 130–050–201). Mouse mono-
cytes were obtained from C57BL6 WT and prkag1¡/-. Briefly,
cells were extracted from tibia and incubated with PE-labeled
anti-ITGA2/CD49b, -PTPRC/CD45R, -CD3E, and -LY76/
Ter119 antibodies (Miltenyi, 130–102–337, 130–102–292,
130-102-600, 130–102–336, respectively). Cells were then sepa-
rated with an autoMACSTM and the negative fraction containing
purified monocytes was treated with murine CSF1 (100 ng/mL).
Purified monocytes from humans and mice were grown in RPMI
1640 medium with glutamax-I (Life Technologies, 61870044)
supplemented with 10% (vol/vol) fetal bovine serum (Life Tech-
nologies, 10270106). Macrophage differentiation (adhesion to
culture flasks and fibroblast-like shape) was visualized using stan-
dard optics (Leica, Paris, France) equipped with a Moticam 2500
camera (Motic, Wetzlar, Germany). Phase images of the cultures
were recorded with a 20£/0.30 PH1 objective with the Motic
Image Plus software (Motic). The human leukemic cell line
K562 (ACC 10, DSMZ) and human prostate carcinoma PC3
cells (ACC 465, DSMZ) cells were respectively grown in RPMI
1640 medium with glutamax-I and in 45% Ham’s F12 C 45%
RPMI 1640 (Life Technologies) supplemented with 10% (vol/
vol) fetal bovine serum.
Flow cytometry
The monocyte differentiation, the cell surface expression of
P2RY6 and autophagy were studied by flow cytometry.44 To ana-
lyze the macrophagic differentiation of monocytes, cells were
washed with ice-cold phosphate-buffered saline (PBS, Life Tech-
nologies, 14190169), and incubated at 4C for 10 min in PBS/
bovine serum albumin (BSA 0.5%; Dutscher, 871002) with
anti-TFRC and anti-CD163 or with anti-ITGAM/CD11b and
anti-EMR1/F4/80 or an isotype control (Miltenyi, 130-091-727,
130-097-628, 130-091-240 and 130-102-379, respectively).
Finally, the cells were washed and fixed in 2% paraformaldehyde
(EMS, 15710). To analyze the cell surface expression of P2RY6,
cells were washed with ice-cold PBS, incubated at 4C for 1 h in
PBS/ BSA (0.5%) with P2RY6 (1:100) or an isotype control
(Santa Cruz Biotechnology, sc-2027), washed and incubated
with secondary antibody (1:1500) for 30 min. Finally, the cells
were washed and fixed in 2% paraformaldehyde. A Cyto-ID

Autophagy Detection Kit was used to monitor autophagic activ-
ity at the cellular level according to the manufacturer’s instruc-
tions (Enzo Life Sciences, ENZ-51031-K200). Briefly, the
488 nm-excitable green fluorescent detection reagent supplied in
the Cyto-ID

Autophagy Detection Kit becomes brightly fluo-
rescent in vesicles produced during autophagy. Fluorescence was
measured by the use of a MACSQuant Analyzer (Miltenyi,
Paris, France).
Immunoblot assays
Cells were lysed for 30 min at 4C in lysis buffer (50 mM
HEPES, pH 7.4, 150 mM NaCl, 20 mM EDTA, 100 mM
NaF, 10 mM Na3VO4, complete protease inhibitor mixture
[Roche, 11836153001], 1% Triton X-100 [Sigma, T9284]).
Lysates were centrifuged at 20,000 g (15 min, 4C) and superna-
tant fractions were supplemented with concentrated sodium
dodecyl sulfate (Euromedex, EU0660). Fifty micrograms of pro-
teins were separated and transferred following standard protocols
before analysis with a chemiluminescence detection kit (GE
Healthcare, RPN2105).
Reverse-transcription and real-time polymerase chain
reaction
RNA was prepared from 5 £ 106 cells using the RNeasy
Mini Kit according to the manufacturer’s protocol (Qiagen,
74104). Each cDNA sample was prepared using superscript
II RT and random primers (Life Technologies, 18064–014
and 48190–011). Real-time polymerase chain reaction (PCR)
was performed using the SyBR Green detection protocol
(Life Technologies, 4367659). Briefly, 5 ng of total cDNA,
125 nM (each) primers, and 10 mL SyBR Green mixture
were used in a total volume of 20 mL. Detection of multiple
endogenous controls (ACTB, RPL32/L32 and UBB) were
used to normalize the results. Specific forward and reverse
primers are accessible upon request.
siRNA knockdown
Small interfering (si) RNAs were introduced into monocytes
or K562 by nucleoporation (Amaxa, VPA-1007, VACA-1003)
of 5 £ 106 monocytes or K562 in 100 mL of nucleofector solu-
tion with 15 nmol of siRNA. Cells were incubated for 24 h with
5 mL of prewarmed complete medium, and CSF1 was subse-
quently added. We used siRNAs (Life Technologies) targeting
PRKAA1/AMPKa1 (HSS108454), PLCG2 (HSS108098),
CAMKK2/CaMKKb (HSS173805), P2RY6 (HSS143211),
PLCB3 (HSS108082), CSF1R (HSS102358), STK11/LKB1
(VHS50411) and, LUCIFERASE as a negative control (Sense: 5’-
CUUACGCUGAGUACUUCGAtt-3’).
Functional assay - (Gentamicin protection assay)
Monocytes (106) were infected for 20 min in RPMI 1640
medium supplemented with 10% fetal calf serum with ampicillin
resistant E. coli K12 (MOI D 50)(Life Technologies, C4040).
The cells were washed 3 times before incubation for 20 min with
RPMI 1640 medium supplemented with 10% fetal calf serum
and gentamicin (50 mg/mL; Life Technologies, 15750–045) to
measure internalized bacteria. The cells were lysed in PBS with
0.1% Triton X-100, and the number of bacteria on LB plates
containing ampicillin (100 mg/mL) were counted. The mean val-
ues of triplicates that were representative of 4 independent experi-
ments were calculated.
Calcium flux assay
Monocytes were loaded using a Fluo-4 Direct Calcium Assay
Kit according to the manufacturer’s instructions (Molecular
Probes, F10471). Calcium release was measured by the use of an
autoMACS Pro Separator (Miltenyi, Paris, France).
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Immunofluorescence
Cells were washed with ice-cold PBS, incubated at 4C for
1 h in PBS/ BSA (0.5%) with P2RY6 (Santa Cruz Biotechnol-
ogy, 1:100) and/or CSF1R (BioLegend, 1:50) antibodies and,
washed and incubated with secondary antibody (1:1500) for
30 min. Finally, the cells were washed and fixed in 2% parafor-
maldehyde and spun on to a microscope slide for 4 min at 800 g
in a Cytospin 3 apparatus (Shandon Thermo Electron Corp,
Paris, France). The cells were then mounted on coverslips and
analyzed with a confocal microscope (Carl Zeiss, Paris, France).
Statistical analysis
Statistical analysis was performed using a paired Student t test
and significance was considered when P values were lower than
0.05. The results are expressed as the mean § SEM.
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